Otonomy, Inc. announced that on February 21, 2020, Heather Preston, M.D. resigned as a member of the Board of Directors of the Company, effective February 28, 2020. On February 27, 2020, the Company announced that, effective March 1, 2020, Ciara Kennedy, Ph.D. has been appointed to the Board, filling the vacancy created as a result of Dr. Preston’s resignation, and to serve as a member of the corporate governance and nominating committee of the Board. Dr. Kennedy will serve as a Class III director, with a term expiring at the Company’s 2020 annual meeting of stockholders. Dr. Kennedy currently serves as President, Chief Executive Officer, and a member of the board of directors of Amplyx Pharmaceuticals. Prior to Amplyx, she served as Chief Operating Officer at Lumena Pharmaceuticals, until the company’s acquisition by Shire Pharmaceuticals, and then continued as Vice President, Head of Cholestatic Liver Disease at Shire post acquisition.